Stay Connected
Atlanta Black Star/Editor's Picks
Editor's PicksList

6 American and Canadian Companies Profiting From the Ebola Virus Outbreak in West Africa

By | Published on October 6, 2014
CommentsComments (2) Add ABS as a preferred source on Google i

The recent outbreak of the Ebola virus has caused further instability, fear and deaths of hundreds in many West African countries, including Guinea, Liberia and Sierra Leone. Ebola is also driving up profits in some corners of the stock market as investors are hedging their bets against which company will be the first to find the cure.

Tekmira Pharmaceuticals Corporation's head office is pictured in Burnaby

Tekmira Pharmaceuticals (NASDAQ: TKMR)

Vancouver-based Tekmira Pharmaceuticals (TKMR) has experienced significant growth since the first case of Ebola was reported in March in Guinea. According to ibtimes.com, stock prices on Tekmira jumped “62 percent between March 3 and March 11, when the outbreak first began.” The stocks have since been up 350 percent from a low just below $7 at this time last year. Tekmira signed a $140 million contract with the U.S. Department of Defense four years ago to develop its treatment, called TKM-Ebola. Now the drug has emerged as one of the leading candidates for possible experimental use.

Last year around the same time, the pharmaceutical company had a market capitalization of $65 million. Fast-forward, and the market cap is now approximately $736 million, based on estimates by marketwatch.com.

Berlin Hospital Prepares For Possible Ebola Cases

BioCryst (NASDAQ:BCRX)

BioCryst Pharmaceuticals, a drug developer in Durham, North Carolina, received a $4.1 million award in federal research funds from the National Institute of Allergy and Infectious Diseases in August. The multimillion-dollar fund is to develop an experimental antiviral drug known by the code BCX4430 as a potential treatment for Ebola.

Last week, according to businessinsider.com, BioCryst shares were up more than 14 percent in after-hours trading. Ycarts.com reports BioCryst’s market cap was at $88 billion last July. This month it is at an astounding $918 billion.

The ABS Newsletter — Stories that matter, in your inbox.

Independent journalism still matters.

We hope this story was worth your time. For over 14 years, Atlanta Black Star has stayed Black-owned and independently run. We didn't get here by waiting on ad budgets that were never built to prioritize us. Our readers did that.

Corporate support for Black media has always been thin. Outlets like ours get roughly 1% of the $170 billion spent on U.S. advertising each year, and that margin is shrinking further as advertisers walk back the DEI-linked commitments they made in 2020. That's the backdrop. It's not why we're asking.

The wider picture isn't any steadier. Newspaper ad revenue has fallen more than 80% since 2005, and local newsrooms are closing at a rate of roughly two a week nationwide. When outlets go under, it's rarely the ones built to center a Black perspective from the ground up that get to stick around.

We know a request for support isn't why you came here. But without readers choosing to fund this work directly, the depth of reporting we can do at home and abroad shrinks along with everyone else's. If you're not in a position to give, that doesn't change how much we value you as a reader.

If you are able to, a recurring contribution does more for us than a single one-time gift, because it lets us plan the next investigation instead of just the next invoice. It takes about 30 seconds, no long form, no account. Thank you for continuing to support independent journalism and freedom of the press.

Give once Give monthly Support another way

Latest from Atlanta Black Star

Back to top